Meridian Bioscience (VIVO) Prelim. Q3 Revenue Misses Consensus

Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022.

For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million. The Diagnostics segment net revenues are expected to be between $41 million and $43 million. The Life Science segment net revenues are expected to be between $25 million and $26 million, of which sales of immunological reagents accounted for approximately 69% and molecular reagents contributed approximately 31%

(Consensus sees Q3 revenue of $69.6 million).

Meridian has not yet completed preparation of its interim financial statements for the third quarter of fiscal 2022 and the information presented herein is a preliminary estimate, subject to change.

You May Also Be Interested In

• SEALSQ posts 131% revenue gain in H1 2026, net loss widens
• Peraso CFO James Sullivan resigns effective October 2026
• Roblox announces standalone apps, browser play, and creator wallet